One hundred and seventeen patients with severe aplastic anemia (SAA) were treated at our institution between 1976 and 1990 with antilymphocyte globulin (ALG) therapy. Seventy-nine (68%) are alive and probability of survival at 14 years, according to Kaplan and Meier, is 62% f 12%. Twenty-six patients developed a late clonal complication: 11 had a myelodysplastic syndrome (MDS) and 17 had paroxysmal nocturnal hemoglobinuria (PNH); two patients had both. The cumulative risk at 10 years is 42%. The development of MDS/PNH after SAA directly affects survival. The probability of being alive at 14 years is 81% f 10% for patients with stable disease and 36% f 13% for those with clonal evolution (P = ,001). To look for predictive signs, we reevaluated peripheral blood and bone marrow cytomorphology at presentation, during regeneration, and in remission. We examined the peripheral blood values for hemoglobin, reticulocytes, granulocytes, thrombocytes, mean corpuscular volume (MCV), and fetal hemoglobin, as well as bone marrow for cellularity, erythropoiesis, myelopoiesis, and mega karyopoiesis. ALG therapy induces slow and incomplete recovery. Although in "remission," ALG patients have lower hemoglo-EVERE APLASTIC ANEMIA (SAA) is defined as a S peripheral pancytopenia due to unexpected failure of the bone marrow (BM). BM transplantation (BMT) or treatment with antilymphocyte globulin (ALG) is the therapy of choice. Both modalities have improved the outcome of patients with SAA.1-5 The long-term follow-up of these patients has shown new findings. Late hematologic complications such as paroxysmal nocturnal hemoglobinuria (PNH) and myelodysplastic syndromes (MDS) are observed with increasing frequency.6-11 So far, identification of the patients at risk is not possible at the time of presentation. New, sophisticated technologies have been introduced to characterize more precisely the disease and to predict outcome. They have not yet been validated in long-term studies. Morphology of the BM has become somewhat neglected, although its application is essential for confirmation of the diagnosis. In contrast to the recently developed in vitro techniques, BM morphology has been obtained for patients treated more than a decade ago and can be reassessed retrospectively. For this reason, we reevaluated the role of peripheral blood (PB) and BM cytology in the characterization of SAA at diagnosis and during follow-up. We took advantage of the fact that we performed BM examinations in all patients at regular intervals before and after treatment.
PATIENTS AND METHODS

Patient Population
A prospective study for the treatment of patients with SAA was initiated at the Kantonsspital Basel in 1976.12J3 Young patients with an HLA-matched sibling donor received an allogeneic BMT, all others were treated with ALG. The treatment protocol as well as the results of the study have been published in detail.12J4 The present analysis includes all 117 patients treated between January 1976 and December 1989 with ALG. The data were evaluated as of January 1, 1990 . Their characteristics are shown in Table 1 .
bin values, higher reticulocyte counts, lower granulocyte and platelet values, and a higher MCV and fetal hemoglobin than normal controls. They retain a reduced number of megakaryocytes and a persistence of atypical monocytes in bone marrow morphology as stigmata of their disease. Patients with late clonal complications show distinct morphologic abnormalities: patients with PNH have higher MCVs, higher granulocyte and reticulocyte counts, and more dyserythropoiesis at diagnosis and a lower hemoglobin with an increased proportion of erythroblasts in the bone marrow in "remission." Patients who later developed MDS are not different from the total patient population at diagnosis. After therapy, these patients are characterized by the presence of ring sideroblasts and atypical monocytes during regeneration and by a persistent increase in MCV, a higher fetal hemoglobin, lower granulocyte values, and megakaryocytic dysplasia during "remission." Thus, routine morphologic follow-up examination of blood and bone marrow can discover patients at risk for late hematologic complications after ALG therapy. o 1992 by The American Society of Hematology.
FoIIow-Up
The follow-up protocol was strictly defined. All patients remained in Basel for at least 3 months after treatment, independent of their recovery. If required, they stayed until they achieved transfusion-independent self-sustaining hematopoiesis. Depending on their clinical status, they were cared for as inpatients or outpatients. Clinical examination and blood counts were performed daily until recovery and then at least three times weekly during the first 3 months. BM cytology and histology was performed before therapy as well as 1,3, and 6 months after therapy and whenever indicated. All patients were called for an annual examination. This annual follow-up examination included investigation of PB values, BM aspiration and biopsy, determination of fetal hemoglobin (Hb F), and screening tests for PNH, including the search for hemosiderin in the urine, acid Ham's, and sucrose lysis tests. All patients were transfusion dependent before therapy. "Remission" was defined as complete independence from transfusions and sustained increments of Hb greater than 100 g/L, granulocyte counts greater than 0.5 x 109/L, and platelet counts greater than 50 X 109/L.
All hematologic complications occurring after successful treatment of the S A A were assessed. They were divided into secondary 338 TlCHELLl ET AL Study Design
All blood counts of all patients before therapy and in remission and all BM smears before and 1 and 3 months after therapy and in remission were systematically reevaluated and blindly quantified. Qualitative evaluation was performed by one hematologist and quantitative parameters of the smears were obtained by two specifically trained medical laboratory technicians without knowledge of the outcome of the patients. To assess morphology during remission, the first marrow taken after the normalization of the PB values was used. BM reevaluation was restricted to BM aspiration.
For the reexamination of the blood counts we considered the following values: total Hb, mean corpuscular volume (MCV), Hb F, granulocytes, reticulocytes, and platelet counts. Each BM examination included the analysis of two smears stained with May-Griinwald-Giemsa and one with Prussian Blue. Total cellularity was scored as aplastic, hypoplastic, normocellular, or hypercelMar. The prevalence of erythropoiesis and myelopoiesis was scored by differentiation of 500 cells and the mye1oid:erythroid ratio (M:E) was established. Megakaryocytes were counted in absolute numbers per smear and the mean of the two preparations was calculated. As normal controls, BM of 10 healthy donors (5 males, 5 females) were evaluated in the same manner. The dysplastic features of all three cell lines (Fig l) , such as dyserythropoiesis, atypical monocytes, and dysmegakaryopoiesis, were assessed semiquantitatively. Dyserythropoiesis was classified into absent, minimal changes (less than 5%) and important abnormalities (more than 5%). Special attention was given to atypical monocytes found either isolated or in clusters of more than 4 cells. An abnormal distribution of megakalyocytes in clusters of more than 4 cells and pathologic forms were recorded. The proportion of ring sideroblasts per 100 erythroblasts in the iron stain was determined.
For the analysis of the morphology as a predictive test for hematologic complications, results of patients presenting a hematologic complication were compared with those of patients in stable remission.
Statistical Analyses
For all numerical variables, mean, standard deviation, median, and range were obtained by the NCSS-statistical programme. The Mann-Whitney U test was used to analyze group differences for morphologic parameters. For an "all or none" comparison, the two-sample proportion test was applied. Analyses of the risk for a later development to clonal disorders were performed according to the method of Kaplan and Meier.15 Log-rank tests with two-sided significance levels were used to compare survival and the risk of a transformation.16 For all statistical analyses, P values 5 .OS were considered significant.
To determine the combined effect of prognostic factors for MDS or PNH, a scoring system was established. All parameters significant in the univariate analysis for a correlation with PNH or MDS were used. The score for PNH includes MCV, reticulocyte and granulocyte counts, and marrow dyserythropoiesis at diagnosis, as well as Hb, dyserythropoiesis, and the proportion of erythroblasts in remission. The score for MDS includes ring sideroblasts and atypical monocytes in clusters during marrow regeneration, as well as MCV, granulocyte counts, Hb F, and marrow dysmegakarypoiesis in remission. Each parameter exceeding the critical value in the univariate analyses was considered as one point in the score. For some patients, all of the parameters could not be analyzed. Therefore, the final score was established as a percentage of positivity. Patients with more than 60% of their score points positive were considered to be high-risk patients.
RESULTS
As of January 1, 1990, 79 of the 117 patients were alive (67%). Thirty-eight patients had died (32%). The probability of survival at 14 years according to the method of Kaplan and Meier is 62% ? 12%. Twenty-eight hematologic complications occurred in 26 ALG-treated patients. There were 11 cases of MDS and 17 cases of PNH (12 had clinical and 5 had laboratory PNH). Two patients had PNH and MDS consecutively. The cumulative risk of developing secondary MDS or PNH after ALG therapy is 42% 2 13% at 10 years (Fig 2) .
The development of MDS/PNH directly affects survival. Seventeen patients suffered a late death, occurring more than 1 year after therapy. Six of the 91 patients with stable disease and 11 of the 26 patients with secondary MDS or PNH died. The causes of late death were aplasia (5 patients) and carcinoma (1 patient) in the group without hematologic complications, and leukemia (8 patients) or PNH (Budd-Chian syndroma, 2 patients; cerebral thrombosis, 1 patient) in patients with secondary MDS/PNH. The cumulative survival in patients with long-term follow-up was 81% 2 10% for those with stable disease and 36% ? 13% for patients with clonal evolution (P = .001) (Fig 3) .
The clinical characteristics of the patients with secondary MDS or PNH are shown in Table 2 . They do not differ from patients with stable remission with regard to age, sex, or ogy. In six patients, material for analyses was insufficient; all were considered as patients with aplastic anemia. Severe hypoplasia was seen in 73 patients, there was complete aplasia in 35, and in 38 some residual hematopoiesis was found. The three cell lines were not affected equally. Erythropoiesis, even when scarce, was usually dominating. Erythropoiesis was almost absent in 32 patients and residual activity was seen in the 79 others. Residual erythroblasts were often encountered in clusters of cells at the same stage of maturation. Of the patients with a residual erythropoiesis, 33 showed no dysplasia, 19 had dyserythropoiesis in less than 5% of the erythroblasts, and 27 had dyserythropoiesis in more than 5% of the erythroblasts. Dysplastic features were frequently associated with megaloblastic traits. Ring sideroblasts could be evaluated in patients with residual erythropoiesis. Twenty-seven of them had ring sideroblasts in 1% to 39% (median, 4%). Twelve patients had ring sideroblasts and dyserythropoiesis in more than 5% of erythroid cells. Myelopoiesis was strongly reduced in 60 preparations and had a residual activity in 51. Atypical monocytes were seen in 23 patients; in six of these, anomalities were found in clusters. None of the patients had an excess of myeloblasts. Megakaryopoiesis was most seriously affected. In 83 patients, no megakaryocytes were found. Twenty-three patients had 1 to 5 megakaryocytes per smear and five patients more than 5. Atypical forms were seen in 5 of the 28 patients with residual megakaryopoiesis. At diagnosis, no micromegakaryocytes typical of MDS were seen in any patient. The mean Hb values and reticulocyte and thrombocyte counts in remission were within normal range, and the mean of the granulocyte counts was only slightly reduced (Table 3) . However, there is considerable patient to patient variation. Half of them had lower than normal granulocyte ( < 2.5 x 109/L) and platelet counts were obtained in a transfusion-free interval of at least 3 months. Thirty-three of 58 ALG-treated patients in remission had an Hb F level greater than 1%. The mean value was 2.9% f 4.0% (range, 0.1% to 21.7%).
Reconstitution of marrow cellularity and hematopoiesis was slow and showed a characteristic pattern (Table 4) . A normal cellular marrow was observed in 10 of 80 patients 1 month after ALG. At 3 months, the cellularity was still decreased in 54 of 94 patients. In remission, as defined by PB values, 40 of 81 had a normal cellularity. The marrow was hypocellular in 23 and hyperplastic in 18. The same pattern was seen for erythropoiesis and myelopoiesis. In early regeneration, even while strongly reduced, the erythropoiesis was dominating and tended to normalize later, while the relative part of myelopoiesis showed the opposite development. Therefore, the M:E ratio was strongly decreased immediately after treatment and normalized with time. At 1 month, the ratio was 0.7 2 0.7. It was 1.2 f 0.5 at 3 months and 1.8 f 1.1 in remission (normal M:E ratio, 2.5 2 1.0). The reconstitution of megakaryopoiesis was significantly delayed. The average number of megakaryocytes (+1 SD) at 1 and 3 months and in remission was 7 2 16,22 + 32, and 42 k 40, respectively. After 1 month, 35%
of the patients and, after 3 months, 17% of the patients still had no megakaryocytes. The time course of the morphologic abnormalities was typical ( Table 4) . Erythoblasts were often present in large clusters of dysplastic cells. Fifty-one of 80 patients had some degree of dyserythropoiesis at 1 month. At 3 months, it was observed in 58 of 94 patients and in remission in 33 of 81. Ring sideroblasts were seen in 47 of 74 patients at 1 month, in 46 of 88 at 3 months, but only in 26 of 78 in remission. Mean values of ring sideroblasts during the three periods are shown in Table 4 . The most striking dysplastic feature of myelopoiesis was the presence of atypical monocytes. At 1 month, they were seen in 34 of 80 patients and were distributed in clusters in 10 of them. At 3 months, they were seen in 46 of 94 (17 in clusters) and in remission in 45 of 81 (19 in clusters). Megakaryocyte distribution and abnormalities could only be evaluated in patients with at least minimal megakaryopoiesis. At 1 month, 15 of 24 patients had a distribution in clusters and five showed dysplasia. At 3 months, 40 of 53 patients showed clusters and 21 dysmegakaryopoiesis; in remission, 40 of 81 had clusters and 19 had morphologic abnormalities.
Late Hematologic Complications After ALG
The differences found between patients with secondary hematologic complications and patients in stable remission are summarized in Tables 5 and 6 . ALG-treated patients who developed PNH had higher reticulocyte and granulocyte counts, an increased MCV, and dyserythropoiesis was more pronounced in the BM at diagnosis. During regeneration, this patient group showed no characteristic pattern. However, in remission, the pathology of the red blood cell population becomes obvious: PNH patients had a lower Hb level, a higher reticulocyte count, and an increased proportion of erythroblasts with dyserythropoietic features in the BM.
Patients who developed secondary MDS showed no characteristic pattern in the PB and BM at diagnosis. However, during regeneration, these patients frequently had sideroachresia and signs of dysplasia of myelopoiesis and megakaryopoiesis. In remission, MDS patients often had increased MCV and Hb F levels. Atypical monocytes and dysplasia of the megakaryocytes persisted to various extents.
In an univariate analysis evaluating parameters before therapy, a reticulocyte count greater than 10 x 109/L (P = .04), a granulocyte count greater than 0.3 x 109/L (P = .Ol), and an MCV level greater than 90 fL (P = .02) correlated with evolution into secondary PNH (Table 5 ). In remission, the same parameters gave different information (Tables 5 and 6 ). Patients with granulocyte counts greater than 2.5 x 109/L (P = .007), an MCV level greater than 103 fL (P = .04), and an Hb F level greater than 1% (P = .03) were at risk for secondary MDS. On the other hand, an Hb less than 140 g/L was predictive for secondary PNH BM morphology at diagnosis is of poor prognostic value. Dyserythropoiesis was the only parameter associated with secondary PNH. There was no predictive parameter for late transformation into MDS (Tables 5 and 6 ). During regeneration, ring sideroblasts (P = .04) and atypical monocytes (P = .Ol), even more so when occurring in clusters (P < .001), were strongly predictive for secondary MDS.
None of the parameters were predictive for secondary PNH. In remission, dyserythropoiesis in more than 5% of the erythroblasts (P = .03) and a relative proportion of erythroblasts greater than 30% (P = .008) were significantly more frequent in patients later developing a second-(P = .007). ary PNH. In contrast, abnormalities of megakaryopoiesis were associated with secondary MDS (P = .02).
The risk score, obtained by combining prognostic criteria, allows for a better identification of patients at risk.
Patients with a score of greater than 60% are at high risk.
The probability of developing secondary MDS is 45% for the high-risk group and 11% (P = .0003) for the low-risk group (Fig 4A) . In 8 of 11 patients who developed secondary MDS, the event would have been predicted by the score. The probability of developing secondary PNH is 47% for the high-risk group and 15% (P = .003) for the low-risk group (Fig 4B) . Accurate predictions could be made for (-) and low risk (-.-) according to a risk score based on morphologic parameters of PB and BM.
PNH in 11 of 15 PNH patients and for the absence of PNH in 83 of 102 patients who did not develop PNH.
DISCUSSION
The prognosis of patients with SAA has been greatly improved with BMT and ALG With the increasing number of long-term survivors, a higher rate of late complications is now observed.6-10 There are basic differences between the two treatment groups. Hematologic reconstitution is usually fast and complete after BMT. Marrow transplantation is likely to cure the disease. In contrast, recovery often takes several months after ALG therapy17 and stigmata of the disease remain despite clinical remission. Immunosuppression, although allowing autologous reconstitution of hematopoiesis, leaves the patient with a "fragile" BM prone to the development of a late complication. ALG-treated patients, therefore, remain at risk of developing hematologic complications, such as MDS or PNH6; BMT-treated patients seldom present such an evolution.18 The development of MDS or PNH after S A A directly affects survival. The probability of being alive at 14 years is 81% for patients with stable disease and 36% for those with clonal evolution.
These considerations imply that the clinical differences observed in patients with S A A are reflected in the morphology. The early phase of autologous BM recovery after immunosuppression is invariably abnormal; it is characterized by a predominant erythropoiesis with dysplastic features and sideroachresia. Myelopoiesis lags behind and shows atypical monocytes. Megakaryopoiesis is the slowest to recover and shows the most preeminent dysplastic features at 3 months after ALG therapy. With ongoing autologous remission, these morphologic abnormalities normalize in some patients and persist in others. They are not found in recipients of BM grafts. Dysplastic features in ALG-treated patients can be interpreted as an indication of a persisting defect in the hematopoietic stem cell.
The morphologic abnormalities in ALG-treated patients are most prominent during the phase of recovery. This observation has not been reported and the reasons behind this prominence remain unknown. A direct toxic effect of horse serum is unlikely. We observed the same pattern of regeneration in patients treated with cylcosporine A or androgens (unpublished observations, 1991). ALG therapy probably acts by two mechanisms: it removes a blocking factor of hematopoiesis and stimulates the release of growth factors, thus provoking an increase in proliferation. 19 Preexisting dysplastic abnormalities can then appear in excess. This proliferation window may transiently label patients with an abnormal cell clone and the morphologic signs in this period can be used as a prognostic factor for a late hematologic complication.20 This is best illustrated by the patients with later MDS. None of the parameters at diagnosis is predictive for a late MDS. During recovery, the morphology of the marrow is more informative. Ring sideroblasts and dysplasia of the myelopoiesis permit the identification of such patients. The clustering of atypical monocytes possibly corresponds to the histologic feature described by Tricot et a1 as abnormal localization of immature myeloid precursors (ALIP)F1 They showed that in patients with MDS, ALIP were associated with a poor prognosis and a higher risk of transformation in leukemiaF2
The presence of morphologic abnormalities is highly predictive of the development of late clonal disorders of hematopoiesis. An increased MCV, higher values of granulocytes and reticulocytes, as well as dyserythropoiesis in the BM at diagnosis are a useful guide for detecting patients at risk for PNH. Residual hematopoiesis in patients with S A A at diagnosis is correlated with a better p r o g n o~i s ,~,~~ but is at the same time associated with a higher risk for a PNH. These patients must be screened routinely for laboratory and clinical PNH.
Once stable remission is achieved, risk factors predicting both an MDS or a PNH can be distinguished. Increased MCV and Hb F levels, as well as lower values of granulocytes in the PB and dysplasia of the megakaryopoiesis correlate with the risk of a late MDS. In contrast, lower Hb levels as well as dyserythropoiesis and an increased proportion of erythroblasts in the BM are associated with late PNH.
The relationship between S A A and MDS has long been This study further supports their close relationship. MDS is a heterogeneous group of disorders.29 It has been suggested that the subgroups of MDS reflect different stages of the same disease rather than separate disorders.3O The early stage of an MDS is characterized by an erythroid hyperplasia with or without ring sideroblasts, followed by a decrease of erythropoiesis and an increase of the proportion of myeloid cells. Leukemic cells appear in the final stage. During autologous recovery of SAA, BM morphology shows a similar sequence as the evolution through the different stages of MDS. Erythropoiesis first dominates, followed by a progressive increase of the myelopoiesis. Ring sideroblasts are typically found early after ALG therapy. In some patients with SAA, the aplastic phase could be the very first stage of an MDS. After successful treatment, the BM can mimic the different stages of the MDS before "normalizing." Years later, some of the aplastic patients will develop a frank leukemia.
Although it is rather old-fashioned method of investigation, cytomorphology of the BM has regained a central place in diagnosis and follow-up in patients with SAA. Longitudinal analyses are possible because the same methods are used as 15 years before. Morphology of blood and BM reflect the persistence of stem cell defect after autologous recovery in aplastic anemia and can identify patients at risk for late hematologic complications. This might become more important in the future with the advent of successful unrelated donor marrow transplantation.
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